ECOR - electroCore, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.8500
+0.0010 (+0.12%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.8490
Open0.8400
Bid1.0400 x 1800
Ask1.5500 x 34100
Day's Range0.8251 - 0.8500
52 Week Range0.3200 - 5.6400
Volume2,558,941
Avg. Volume1,032,577
Market Cap32.411M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-1.3310
Earnings DateAug 11, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    electroCore to Participate in Three Upcoming Virtual Investor Conferences

    BASKING RIDGE, N.J., July 09, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Dan Goldberger, Chief Executive.

  • GlobeNewswire

    electroCore, Inc. to Present at Little Grapevine’s G1 Microcap Virtual Conference

    BASKING RIDGE, N.J., May 29, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that that a prerecorded virtual presentation featuring Dan Goldberger, Chief Executive Officer, will be available at Little Grapevine™ (www.littlegrapevine.com) beginning today, May 29, 2020, at 10:30 a.m. Eastern Standard Time. Accompanying the presentation will be a short executive introduction, as well as a brief Q&A with Mr. Goldberger. No fee is required to join or view the company’s Little Grapevine Conference presentation, as it is open to the public.

  • ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates
    Zacks

    ElectroCore, Inc. (ECOR) Reports Q1 Loss, Tops Revenue Estimates

    electroCore, Inc. (ECOR) delivered earnings and revenue surprises of -4.00% and 0.55%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    electroCore Announces First Quarter Financial Results

    BASKING RIDGE, N.J., May 14, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced first quarter 2020 financial results and provided an operational update. Received 510(k) clearance from FDA to expand the gammaCore label into migraine prevention. Announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore (nVNS) in the treatment of cluster headache in adults, through September 2020.

  • GlobeNewswire

    electroCore to Announce First Quarter Ended March 31, 2020 Financial Results on Thursday, May 14

    BASKING RIDGE, N.J., May 07, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for.

  • GlobeNewswire

    electroCore Provides Update on COVID-19 Clinical Initiatives

    BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today provided an update on ongoing nVNS COVID-19 initiatives. The company announced today that an investigator-initiated, randomized, controlled clinical trial of nVNS therapy has commenced enrolling COVID-19 patients in Spain.

  • GlobeNewswire

    electroCore Provides Business Update and Select First Quarter 2020 Guidance

    BASKING RIDGE, N.J., April 17, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today provided a business update, and introduced select preliminary unaudited guidance for the first quarter of 2020. “As we and the rest of the world grapple with the humanitarian crisis and economic uncertainties brought on by the ongoing COVID-19 pandemic, we continue to advance toward our goal of making our gammaCore Sapphire™ non-invasive vagus nerve stimulation (nVNS) technology  available to the broadest possible patient population within our approved adult headache indications,” said Daniel Goldberger, Chief Executive Officer. Expansion of the gammaCore label: On March 26, 2020, the company was informed that it had received Section 510(k) clearance from the FDA of its submission seeking to expand the label indication of its gammaCore therapy to include the prevention of migraine in adult patients.

  • GlobeNewswire

    electroCore, Inc. Announces Extension of NHS England’s Innovation and Technology Payment (ITP) Program to Fund Continued Use of gammaCore™ in the U.K.

    BASKING RIDGE, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service (NHS) has exercised its option to extend the Innovation and Technology Payment (ITP) Program for the use of gammaCore in the treatment of cluster headache in adults. The extension will run through September 2020 and via this program, which started in April 2019, gammaCore will continue to be reimbursed for those patients in England who suffer from cluster headache and respond to our therapy.

  • GlobeNewswire

    electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19

    BASKING RIDGE, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate the study and clinical use of its gammaCore SapphireTM non-invasive vagus nerve stimulation therapy, or nVNS, for respiratory symptoms associated with COVID-19. The EUA includes data from early clinical and non-clinical work that examined the use of the company’s VNS, including non-invasive therapy, in several pilot studies that involved patients with a variety of respiratory disorders.

  • GlobeNewswire

    electroCore Announces 510(k) Clearance of gammaCore™ Label Expansion into Migraine Prevention

    BASKING RIDGE, N.J., March 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has received Section 510(k) clearance from the U.S. Food and Drug Administration (FDA) of the company’s submission seeking to expand the label indication of its gammaCore therapy to include the prevention of migraine in adult patients. “We are grateful to the FDA for clearing the expanded use of our novel gammaCore vagus nerve stimulation device into the prevention of migraine headache in adults who frequently suffer from this incapacitating condition,” stated  Peter Staats M.D., Chief Medical Officer of electroCore.

  • GlobeNewswire

    electroCore Announces Common Stock Purchase Agreement for up to $25 Million with Lincoln Park Capital

    BASKING RIDGE, N.J., March 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into a common stock purchase agreement of up to $25 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor. Under the terms of the purchase agreement, electroCore will, at its sole option and discretion, have the right, but not the obligation to sell up to $25 million of its common stock to Lincoln Park over a 36-month period.

  • GlobeNewswire

    electroCore Announces Changes to its Board of Directors

    BASKING RIDGE, N.J., March 26, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced the appointments of three new independent members to its Board of Directors effective April 2, 2020. The newly appointed board members are John Gandolfo, Thomas Patton and Peter Cuneo.

  • electroCore, Inc. (NASDAQ:ECOR) Just Reported, And Analysts Assigned A US$5.13 Price Target
    Simply Wall St.

    electroCore, Inc. (NASDAQ:ECOR) Just Reported, And Analysts Assigned A US$5.13 Price Target

    The investors in electroCore, Inc.'s (NASDAQ:ECOR) will be rubbing their hands together with glee today, after the...

  • GlobeNewswire

    electroCore Announces Fourth Quarter and Full Year 2019 Financial Results

    Continued growth in VA and U.K. Channels Company to host conference call and webcast today, March 23, 2020 at 4:45 pm  ET BASKING RIDGE, N.J., March 23, 2020 -- electroCore,.

  • ACCESSWIRE

    electroCore, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 23, 2020 / electroCore, Inc. (NASDAQ:ECOR) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 23, 2020 at 4:45 PM ...

  • GlobeNewswire

    electroCore to Announce Fourth Quarter and Year Ended December 31, 2019 Financial Results on Monday, March 23

    BASKING RIDGE, N.J., March 19, 2020 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for.

  • GlobeNewswire

    electroCore, Inc. Announces Rebate Agreement with Ascent Health Services for gammaCore Preferred Brand Coverage on all Express Scripts Standard National Formularies

    BASKING RIDGE, N.J., Jan. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of Express Scripts, one of the nation’s leading pharmacy benefit managers (PBMs) headquartered in St. Louis, has elected to make gammaCoreTM a preferred brand on all of its Standard National Formularies for those benefit designs that do not differentiate between drugs and devices at a monthly co-pay of roughly $25- $45.

  • Some electroCore (NASDAQ:ECOR) Shareholders Have Taken A Painful 73% Share Price Drop
    Simply Wall St.

    Some electroCore (NASDAQ:ECOR) Shareholders Have Taken A Painful 73% Share Price Drop

    Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...

  • GlobeNewswire

    electroCore Provides Business Update and Select Financial Guidance

    BASKING RIDGE, N.J., Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth quarter of 2019, and full-year revenue guidance for 2020. FSS: The company’s decision to redeploy a significant portion of its sales function to FSS is having a positive impact, as 54 Veterans Administration (VA) and Department of Defense (DoD) military treatment facilities purchased gammaCore™ products during the fourth quarter, up from 48 during the third quarter of 2019 and 35 during the second quarter of 2019.

  • GlobeNewswire

    electroCore Announces Board of Directors Transition

    BASKING RIDGE, N.J., Dec. 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox, will resign from the Board effective March 31, 2020. Ms. Cox also served on electroCore’s Audit and Nominating and Governance Committees. Michael Atieh, who joined the company’s Board in June 2018, will assume the role of Chairman.

  • Is electroCore, Inc. (ECOR) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is electroCore, Inc. (ECOR) Going To Burn These Hedge Funds ?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • GlobeNewswire

    NICE Recommends the Use of gammaCore for the Treatment of Cluster Headache in the NHS

    NICE has today published a medical technologies guidance document recommending the use of gammaCore within the NHS for the acute and preventive treatment of cluster headache in the U.K. LONDON and BASKING RIDGE, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (ECOR), a commercial-stage bioelectronic medicine company, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has published its medical technologies guidance for National Health Service (NHS) professionals titled, ‘gammaCore for Cluster Headache’ recommending the use of gammaCore, a non-invasive vagus nerve stimulator (nVNS), for the acute and preventive treatment of cluster headache in adults.

  • GlobeNewswire

    electroCore to Present at the Two December Investor Conferences

    BASKING RIDGE, N.J., Nov. 26, 2019 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, Chief Executive.

  • FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against electroCore, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
    ACCESSWIRE

    FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against electroCore, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    LOS ANGELES, CA / ACCESSWIRE / November 25, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against electroCore, Inc. ("electroCore" or "the Company") (NASDAQ:ECOR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's shares pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's June 2018 initial public offering ("IPO"); and/or purchased or otherwise acquired electroCore securities between June 22, 2018 and September 25, 2019, inclusive (the "Class Period"), are encouraged to contact the firm before November 25, 2019.

  • ACCESSWIRE

    DEADLINE ALERT - electroCore, Inc. (ECOR) - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action and Lead Deadline: November 25, 2019

    NEW YORK, NY / ACCESSWIRE / November 25, 2019 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against electroCore, Inc. ("electroCore" or the "Company") (ECOR) and certain of its officers, on behalf of shareholders who purchased electroCore securities: (a) pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's June 2018 initial public offering ("IPO" or the "Offering") and/or (b) between June 22, 2018 and September 25, 2019, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.